NYXH trades 257.1% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NYXH achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Nyxoah S.A. (NYXH) has a Wall Street consensus price target of $6.00, based on estimates from 5 covering analysts. With the stock currently trading at $1.68, this represents a potential upside of +257.1%. The company has a market capitalization of $63M.
Analyst price targets range from a low of $5.00 to a high of $7.00, representing a 33% spread in expectations. The median target of $6.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NYXH trades at a trailing P/E of -0.6x. Analysts expect EPS to grow +23.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
INSPInspire Medical Systems, Inc. | $1.4B | $50.08 | $56.00 | +11.8% | Hold | 55.9x | 27 |
LIVNLivaNova PLC | $4.6B | $83.58 | $81.43 | -2.6% | Buy | 19.7x | 15 |
AVAVAeroVironment, Inc. | $8.2B | $162.53 | $222.78 | +37.1% | Buy | 49.4x | 28 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
ELMDElectromed, Inc. | $378M | $45.70 | $38.00 | -16.8% | Buy | 37.6x | 5 |
RMTIRockwell Medical, Inc. | $24M | $6.10 | — | — | — | — | — |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
Quick answers to the most common questions about buying NYXH stock.
The consensus Wall Street price target for NYXH is $6, representing 257.1% upside from the current price of $1.68. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NYXH has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies 257.1% upside from current levels.
NYXH's current price is $1.68 with a consensus target of $6 (257.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for NYXH, while the most conservative target is $5. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
NYXH is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NYXH stock forecast based on 5 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $5 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NYXH, with a "Buy" consensus rating and $6 price target (257.1% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NYXH analyst price targets range from $5 to $7, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.